Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Robert Muldoon (NPI 1841277589)

Field	Value
Entity Type	Individual
Organization	Robert Muldoon
Address	133 Harmony Park
City	Hot Springs
State	AR
ZIP	71913
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 23, 2005

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the dataset: reported lifetime Medicare revenue of $3.2M and no Medicaid billing on file (“none below”), which indicates the practice’s publicly reported activity is concentrated in Medicare rather than a mixed Medicare/Medicaid payer mix. Absence of Medicaid claims should be considered when comparing patient access or coverage patterns against in‑state peers.

Revenue is highly concentrated in a small number of high-cost oncology items: the precomputed top‑3 Medicare codes account for 67.8% of the provider’s total Medicare revenue, with J9271 ($1.1M, 35.2%), J9299 ($781K, 25.5%), and 78815 ($214.9K, 7.0%) together driving the majority of receipts. That concentration signals dependence on a handful of expensive systemic therapies and imaging procedures for overall revenue.

Code mix aligns with an oncology infusion and diagnostic practice: Hematology & Oncology taxonomy plus large volumes and revenues for checkpoint inhibitors (J9271, J9299), PET/CT imaging (78815) and a diagnostic radiopharmaceutical (A9595, $195.6K). The presence of M0010 (EOM monthly enhanced oncology services) further supports that this provider bills for ongoing oncology care management and enhanced oncology model services rather than only episodic procedures.

Competitive standing for the top oncology drug codes is solid but not dominant: J9271 ranks #227 of 1841 providers nationally (88th percentile; typical, unremarkable volume) and J9299 ranks #58 of 505 providers nationally (89th percentile; typical, unremarkable volume). Those percentiles indicate the practice sits above median national activity for these expensive agents but is still described in the data as typical relative to high‑volume specialist peers.

Office evaluation-and-management and administration activity are high relative to national peers: 99213 is an extreme outlier (rank #4161 of 457151, 99th percentile; extreme outlier, far above typical national volume) and 99214 ranks in the 97th percentile (notably above typical national volume), while 96372 also appears as an extreme outlier (99th percentile). This pattern suggests heavy throughput of clinic visits and frequent administration/injection services consistent with an active infusion practice.

Several supportive care and specialty drug codes are reported at above‑typical or typical levels: J0885 epoetin alfa ranks #74 of 953 providers (92th percentile; notably above typical national volume) and 96413 (chemotherapy administration) is in the 96th percentile (notably above typical national volume), whereas A9595 (piflufolastat f-18) is in the 66th percentile (typical, unremarkable volume). These placements indicate consistent provision of both chemotherapy and adjunctive/supportive agents alongside advanced diagnostic testing.

There is a mixed picture across biosimilars and newer agents: Q5119 (rituximab biosimilar) and J1442 (filgrastim) are present at typical volumes for their peer groups (Q5119 at 66th percentile; J1442 ranks among a small set of providers), while Q5122 (pegfilgrastim biosimilar, 6th percentile; typical, unremarkable volume) shows relatively low national standing. This suggests selective use of biosimilars and variability in adoption or billing volume for specific supportive biologics.

The provider has long tenure in the dataset, with the NPI enumerated on 2005-12-23 (~21 years ago), indicating an established practice history. Combined with the code mix (high‑cost immunotherapies, PET imaging, oncology E/M billing and infusion administration), the tenure supports interpretation of observed patterns as an experienced hematology/oncology practice rather than a new entrant with transient billing spikes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

70 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	25,100	$40	$1.1M
J9299	Injection, nivolumab, 1 mg	32,540	$20	$781K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	220	$1,000	$214.9K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	320	$620	$195.6K
J0897	Injection, denosumab, 1 mg	8,700	$20	$165.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	920	$90	$81K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	12,320	$10	$73.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,190	$60	$68.8K
J1437	Injection, ferric derisomaltose, 10 mg	3,800	$20	$60.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	700	$90	$60.7K

Showing 1–10 of 70

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 70 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Robert Muldoon — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

70 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	40	20,700	$40	$896.3K
J9299	3	30	15,660	$20	$432.9K
J1437	17	20	6,450	$20	$107.8K
A9595	1	10	110	$570	$90.9K
J0897	30	160	2,580	$20	$89.7K
78815	26	100	90	$550	$83.7K
Q5119	2	10	3,280	$20	$73.2K
J0885	8	40	4,070	$10	$38K
96413	19	80	380	$90	$36.6K
A9552	18	40	180	$150	$28.9K

Showing 1–10 of 70

Related Providers

Other providers that share a Tax Identification Number (TIN) with Robert Muldoon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
American Oncology Partners PA	OH	Hematology & Oncology Physician	$0	$11.8M
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
David Smith	MD	Hematology & Oncology Physician	$6.4M	$0
Stephen Divers	AR	Hematology & Oncology Physician	$3.9M	$1.5K
Bradley Sumrall	GA	Medical Oncology Physician	$3.1M	$0
Linda Hendricks	GA	Specialist	$3.1M	$0
Sue Tsuda	AR	Medical Oncology Physician	$3.1M	$0

Nearby Providers

Other providers in the same ZIP code as Robert Muldoon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rock Dental Arkansas PLLC	AR	Dentist	$0	$128.8M
Superior Senior Care	AR	In Home Supportive Care Agency	$0	$22.5M
Ouachita Regional Counseling & Mental Health Center, Inc.	AR	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$22.4M
Chi St Vincent Hospital Hot Springs	AR	General Acute Care Hospital	$0	$16.4M
Chi St. Vincent Medical Group Hot Springs	AR	Specialist	$0	$13.8M
Tlc Home Care Of Arkansas	AR	In Home Supportive Care Agency	$0	$7M
Little Bitty City Therapeutic Services LLC	AR	Developmental Disabilities Clinic/Center	$0	$6.9M
Healthy Connections Incorporated	AR	Federally Qualified Health Center (FQHC)	$0	$5.5M
Abilities Unlimited Of Hot Springs Ar Inc	AR	Developmentally Disabled Services Day Training Agency	$0	$4.9M
A-o-m-s, PLLC	AR	Oral and Maxillofacial Surgery (Dentist)	$0	$4.2M

Robert Muldoon — Billing Profile & Reimbursement Data

Sign up for Robert Muldoon — Billing Profile & Reimbursement Data policy alerts

Robert Muldoon — Billing Profile & Reimbursement Data

Sign up for Robert Muldoon — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References